The M184V mutation in HIV-1 reverse transcriptase reduces the restoration of wild-type replication by attenuated viruses

AIDS

Volumn 16, Issue 18, 2002, Pages 2391-2398

  Wei, Xin ^a,b   Liang, Chen ^a,b   Götte, Matthias ^a,b   Wainberg, Mark A ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

HIV 1 reverse transcriptase; Initiation; M184V; TRNALys3

Indexed keywords

LAMIVUDINE; LYSINE TRANSFER RNA; RNA DIRECTED DNA POLYMERASE; SINGLE STRANDED DNA; VIRUS DNA;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DNA SYNTHESIS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION; REVERTANT; SITE DIRECTED MUTAGENESIS; TISSUE CULTURE; VIRUS ATTENUATION; VIRUS GENOME; VIRUS REPLICATION;

CELLS, CULTURED; DNA, VIRAL; GENE DELETION; HIV INFECTIONS; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; MUTATION; NUCLEIC ACID AMPLIFICATION TECHNIQUES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, VIRAL; SEQUENCE ANALYSIS, DNA; TRANSCRIPTION FACTORS; VIRUS REPLICATION;

EID: 0037032908     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200212060-00003     Document Type: Article

References (30)

1. Emini EA, Fan HY. Immunological and pharmacological approaches to the control of retroviral infections. In: Retroviruses. Edited by Coffin JM, Hughes SH, Varmus HE. Cold Spring Harbor, New York: Cold Spring Harbor Laboratory Press; 1997:637-708.
2. Bebenek K, Kunkel TA. The fidelity of retroviral reverse transcriptase. In: Reverse Transcriptase. Edited by Skalka AM, Goff SP. Cold Spring Harbor, New York: Cold Spring Harbor Laboratory Press; 1993:85-102.
3. Argos P. A sequence motif in many polymerases. Nucl Acids Res 1988, 16:9909-9916.
4. Tisdale M, Kemp SD, Parry NR, Larder BA. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3′-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proc Natl Acad Sci USA 1993, 90:5653-5656.
5. Gu Z, Gao Q, Li X, Parniak MA, Warnberg MA. Novel mutation in the human immunodeficiency virus type 1 reverse transcriptase gene that encodes cross-resistance to 2′, 3′-dideoxyinosine and 2′, 3′-dideoxycytidine. J Virol 1992, 66:7128-7135.
6. Gao Q, Gu Z, Parniak MA, Cameron J, Cammack N, Boucher C, et al. The same mutation that encodes low-level human immunodeficiency virus type 1 resistance to 2′, 3′-dideoxyinosine and 2′, 3′-dideoxycytidine confers high-level resistance to the (-) enantiomer of 2′, 3′-dideoxy-3′-thiacytidine. Antimicrob Agents Chemother 1993, 37:1390-1392.
7. Tisdale M, Alnadaf T, Cousens D. Combination of mutations in human immunodeficiency virus type 1 reverse transcriptase required for resistance to the carbocyclic nucleoside 1592U89. Antimicrob Agents Chemother 1997, 41:1094-1098.
8. Walter H, Schmidt B, Werwein M, Schwingel E, Korn K. Prediction of abacavir resistance from genotypic data: Impact of zidovudine and lamivudine resistance in vitro and in vivo. Antimicrob Agents Chemother 2002, 46:89-94.
9. Wakefield JK, Jablonski SA, Morrow CD. In vitro enzymatic activity of human immunodeficiency virus type 1 reverse transcriptase mutants in the highly conserved YMDD amino acid motif correlates with the infectious potential of the proviral genome. J Virol 1992, 66:6806-6812.
10. Larder BA, Kemp SD, Harrigan PR. Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science 1995, 269:696-699.
11. Back NK, Nijhuis M, Keulen W, Boucher CA, Oude Essink BO, van Kuilenburg AB, et al. Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme. EMBO J 1996, 15:4040-4049.
12. Wainberg MA, Drosopoulos WC, Salomon H, Hsu M, Borkow G, Parniak MA, et al. Enhanced fidelity of 3TC-selected mutant HIV-1 reverse transcriptase. Science 1996, 271:1282-1285.
13. Hsu M, Inouye P, Rezende L, Richard N, Li Z, Prasad VR, et al. Higher fidelity of RNA-dependent DNA mispair extension by M184V drug- resistant than wild-type reverse transcriptase of human immunodeficiency virus type 1. Nucl Acids Res 1997, 25:4532-4536.
14. Feng JY, Anderson KS. Mechanistic studies examining the efficiency and fidelity of DNA synthesis by the 3TC-resistant mutant (184V) of HIV-1 reverse transcriptase. Biochemistry 1999, 38:9440-9448.
15. Isel C, Ehresmann C, Keith G, Ehresmann B, Marquet R. Initiation of reverse transcription of HIV-1: Secondary structure of the HIV-1 RNA/tRNA(3Lys) (template/primer). J Mol Biol 1995, 247:236-250.
16. Liang C, Li X, Rong L, Inouye P, Quan Y, Kleiman L, et al. The importance of the A-rich loop in human immunodeficiency virus type 1 reverse transcription and infectivity. J Virol 1997, 71:5750-5757.
17. Isel C, Keith G, Ehresmann B, Ehresmann C and Marquet R. Mutational analysis of the tRNA3Lys/HIV-1 RNA (primer/template) complex. Nucl Acids Res 1998, 26:1198-1204.
18. Zhang Z, Kang SM, Morrow CD. Genetic evidence of the interaction between tRNA(Lys, 3) and US facilitating efficient initiation of reverse transcription by truman immunodeficiency virus type 1. AIDS Res Hum Retroviruses 1998, 14:979-988.
19. Wei X, Gotte M, Wainberg MA. Human immunodeficiency virus type-1 reverse transcription can he inhibited in vitro by oligonucleotides that target both natural and synthetic tRNA primers. Nucl Acids Res 2000, 28:3065-3074.
20. Le Grice SF, Cameron CE, Benkovic SJ, Purification and characterization of human immunodeficiency virus type 1 reverse transcriptase. Meth Enzymol 1995, 262:130-144.
21. Arts EJ, Li X, Gu Z, Kleiman L, Parniak MA, Wainberg MA. Comparison of deoxyoligonucleotide and tRNA(Lys-3) as primers in an endogenous human immunodeficiency virus-1 in vitro reverse transcription/template-switching reaction. J Biol Chem 1994, 269:14672-14680.
22. Gunthard HF, Wong JK, Ignacio CC, Guatelli JC, Riggs NL, Havlir DV, et al. Human immunodeficiency virus replication and genotypic resistance in blood and lymph nodes after a year of potent antiretroviral therapy. J Virol 1998, 72:2422-2428.
23. Martinez-Picado J, de Pasquale MP, Kartsonis N, Hanna GJ, Wong J, Finzi D, et al. Antiretroviral resistance during successful therapy of HIV type 1 infection. Proc Natl Acad Sci USA 2000, 97:10948-10953.
24. Gotte M, Arion D, Parniak MA, Wainberg MA. The M184V mutation in the reverse transcriptase of human immunodeficiency virus type 1 impairs rescue of chain-terminated DNA synthesis. J Virol 2000, 74:3579-3585.
25. Li Y, Zhang Z, Wakefield JK, Kang SM and Morrow CD. Nucleotide substitutions within US are critical for efficient reverse transcription of human immunodeficiency virus type 1 with a primer binding site complementary to tRNA(His). J Virol 1997, 71:6315-6322.
26. Isel C, Lanchy JM, Le Grice SF, Ehresmann B, Ehresmann C and Marquet R. Specific initiation and switch to elongation of human immunodeficiency virus type 1 reverse transcription require the post-transcriptional modifications of primer tRNA3Lys. EMBO J 1996, 15:917-924.
27. Liang C, Rong L, Gotte M, Li X, Quan Y, Kleiman L, et al. Mechanistic studies of early pausing events during initiation of HIV-1 reverse transcription. J Biol Chem 1998, 273:21309-21315.
28. Thrall SH, Krebs R, Wohrl BM, Cellai L, Goody RS and Restle T. et al. Pre-steady-state kinetic characterization of RNA-primed initiation of transcription by HIV-1 reverse transcriptase and analysis of the transition to a processive DNA-primed polymerization mode. Biochemistry 1998, 37:13349-13358.
29. Lanchy JM, Keith G, Le Grice SF, Ehresmann B, Ehresmann C and Marquet R, et al. Contacts between reverse transcriptase and the primer strand govern the transition from initiation to elongation of HIV-1 reverse transcription. J Biol Chem 1998, 273:24425-24432.
30. Lanchy JM, Isel C, Keith G, Le Grice SFJ. Ehresmann B, Ehresmann C, et al. Dynamics of the HIV-1 reverse transcription complex during initiation of DNA synthesis. J Biol Chem 2000, 275:12306-12312.